whether patients need additional monitoring if they're switched from Coumadin to one of the generics
October 2001
There's a lot of confusion about whether patients need additional monitoring if they're switched from Coumadin to one of the generics.
A recent labelling change for warfarin removed the recommendation to monitor prothrombin when switching from Coumadin.
Taro is promoting that this means no additional INR testing is needed when patients are switched to Taro-warfarin.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive